Literature DB >> 23216578

Regulators of synaptic transmission: roles in the pathogenesis and treatment of epilepsy.

Pablo M Casillas-Espinosa1, Kim L Powell, Terence J O'Brien.   

Abstract

Synaptic transmission is the communication between a presynaptic and a postsynaptic neuron, and the subsequent processing of the signal. These processes are complex and highly regulated, reflecting their importance in normal brain functioning and homeostasis. Sustaining synaptic transmission depends on the continuing cycle of synaptic vesicle formation, release, and endocytosis, which requires proteins such as dynamin, syndapin, synapsin, and synaptic vesicle protein 2A. Synaptic transmission is regulated by diverse mechanisms, including presynaptic modulators of synaptic vesicle formation and release, postsynaptic receptors and signaling, and modulators of neurotransmission. Neurotransmitters released presynaptically can bind to their postsynaptic receptors, the inhibitory γ-aminobutyric acid (GABA)ergic receptors or the excitatory glutamate receptors. Once released, glutamate activates a variety of postsynaptic receptors including α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), N-methyl-D-aspartate (NMDA), kainate, and metabotropic receptors. The activation of the receptors triggers downstream signaling cascades generating a vast array of effects, which can be modulated by a numerous auxiliary regulatory subunits. Moreover, different neuropeptides such as neuropeptide Y, brain-derived neurotrophic factor (BDNF), somatostatin, ghrelin, and galanin, act as regulators of diverse synaptic functions and along with the classic neurotransmitters. Abnormalities in the regulation of synaptic transmission play a critical role in the pathogenesis of numerous brain diseases, including epilepsy. This review focuses on the different mechanisms involved in the regulation of synaptic transmission, which may play a role in the pathogenesis of epilepsy: the presynaptic modulators of synaptic vesicle formation and release, postsynaptic receptors, and modulators of neurotransmission, including the mechanism by which drugs can modulate the frequency and severity of epileptic seizures. Wiley Periodicals, Inc.
© 2012 International League Against Epilepsy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23216578     DOI: 10.1111/epi.12034

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  42 in total

1.  The impact of brain-derived neurotrophic factor Val66Met polymorphism on cognition and functional brain networks in patients with intractable partial epilepsy.

Authors:  Meneka K Sidhu; Pamela J Thompson; Britta Wandschneider; Alexandra Foulkes; Jane de Tisi; Jason Stretton; Marina Perona; Maria Thom; Silvia B Bonelli; Jane Burdett; Elaine Williams; John S Duncan; Mar Matarin
Journal:  CNS Neurosci Ther       Date:  2018-06-27       Impact factor: 5.243

2.  Evaluating the Role of Genetic Variants on first-line antiepileptic drug response in North India: Significance of SCN1A and GABRA1 Gene Variants in Phenytoin Monotherapy and its Serum Drug Levels.

Authors:  Ruchi Baghel; Sandeep Grover; Harpreet Kaur; Ajay Jajodia; Chitra Rawat; Ankit Srivastava; Suman Kushwaha; Rachna Agarwal; Sangeeta Sharma; Ritushree Kukreti
Journal:  CNS Neurosci Ther       Date:  2016-06-01       Impact factor: 5.243

3.  PTEN Loss Increases the Connectivity of Fast Synaptic Motifs and Functional Connectivity in a Developing Hippocampal Network.

Authors:  Caitlynn M Barrows; Matthew P McCabe; Hongmei Chen; John W Swann; Matthew C Weston
Journal:  J Neurosci       Date:  2017-07-27       Impact factor: 6.167

4.  Disrupted Excitatory Synaptic Contacts and Altered Neuronal Network Activity Underpins the Neurological Phenotype in PCDH19-Clustering Epilepsy (PCDH19-CE).

Authors:  Stefka Mincheva-Tasheva; Alvaro F Nieto Guil; Claire C Homan; Jozef Gecz; Paul Q Thomas
Journal:  Mol Neurobiol       Date:  2021-01-07       Impact factor: 5.590

5.  Preclinical evaluation of intravenous NAX 810-2, a novel GalR2-preferring analog, for anticonvulsant efficacy and pharmacokinetics.

Authors:  Cameron S Metcalf; Brian D Klein; Daniel R McDougle; Liuyin Zhang; Dan Kaufmann; Grzegorz Bulaj; H Steve White
Journal:  Epilepsia       Date:  2017-01-18       Impact factor: 5.864

6.  Proteome Analysis of Potential Synaptic Vesicle Cycle Biomarkers in the Cerebrospinal Fluid of Patients with Sporadic Creutzfeldt-Jakob Disease.

Authors:  Chunyu Wang; Deming Zhao; Syed Zahid Ali Shah; Wei Yang; Chaosi Li; Lifeng Yang
Journal:  Mol Neurobiol       Date:  2016-08-25       Impact factor: 5.590

7.  Peripherally restricted acute phase response to a viral mimic alters hippocampal gene expression.

Authors:  Lindsay T Michalovicz; Gregory W Konat
Journal:  Metab Brain Dis       Date:  2013-12-24       Impact factor: 3.584

Review 8.  Main path and byways: non-vesicular glutamate release by system xc(-) as an important modifier of glutamatergic neurotransmission.

Authors:  Ann Massie; Séverine Boillée; Sandra Hewett; Lori Knackstedt; Jan Lewerenz
Journal:  J Neurochem       Date:  2015-09-29       Impact factor: 5.372

9.  Impact of rapamycin on status epilepticus induced hippocampal pathology and weight gain.

Authors:  Michael S Hester; Bethany E Hosford; Victor R Santos; Shatrunjai P Singh; Isaiah J Rolle; Candi L LaSarge; John P Liska; Norberto Garcia-Cairasco; Steve C Danzer
Journal:  Exp Neurol       Date:  2016-03-17       Impact factor: 5.330

10.  Whole-brain MRI phenotyping in dysplasia-related frontal lobe epilepsy.

Authors:  Seok-Jun Hong; Boris C Bernhardt; Dewi S Schrader; Neda Bernasconi; Andrea Bernasconi
Journal:  Neurology       Date:  2016-01-13       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.